Our history is written day by day, thanks to the vision of our shareholders and the talent of our employees. We care about your health and quality of life.
Stendhal is created as a pharmaceutical company.
A group of Mexican investors acquires Stendhal. A comprehensive transformation takes place: our philosophy and business mission are renewed, shaping us into the company we are today.
The manufacturing site is remodeled following the highest world-class standards. The first product line for the treatment of HIV/AIDS is launched. The HIV Business Unit is created.
Neurology and Neurosciences
We delve into Neurology, launching the first monoclonal antibody for the treatment of multiple sclerosis. The Neurosciences Business Unit is created.
Stendhal partners with Eicopen Pharma, reaching out to countries in Central America and the Andean Region.
Stendhal leader in innovative therapies
Stendhal becomes the indisputable leader in the treatment of HIV/AIDS and Multiple Sclerosis thanks to innovative therapies in areas such as critical care and genetic disorders and diseases.
Trade agreements are initiated to include cardiovascular molecules in our portfolio. The Cardiovascular Business Unit is created, and we launch our first molecule for Arterial Hypertension.
Rise to the Top
Stendhal secures its spot in various national rankings as one of the most important pharmaceutical companies in Mexico.
Central Nervous System and Oncology
Dimethyl fumarate, an innovative treatment for Multiple Sclerosis, is incorporated into our product portfolio.
Work begins on new molecules for advanced Oncology therapy.
Stendhal forges a strategic alliance to increase the distribution and outreach of Primary Care products in Mexico, Central America, and the Caribbean.
Methoxyflurane is added to the portfolio for acute, moderate, or severe pain; it contributes to the effective and safe treatment of patients.